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SUMMARY
Background. Effective treatment protocols development for West syndrome (WS) is scientifically and eco-
nomically significant.
Aim. To evaluate the comparative short term efficacy and tolerability of tetracosactide at a dose of 0.03–
0.05 mg/kg and dexamethasone at a dose of 0.3–0.5 mg/kg both combined with valproate at a dose of 
30–40 mg/kg/day for WS therapy. The regimen was: 1 injection daily for 10 days, following with 5 injec-
tions every other day, then 5 injections every two days, plus a valproate.
Material and Methods. 79 infants (Group 1) received tetracosactide, 18 infants (Group 2) – dexametha-
sone. The demographic data and the main characteristics of WS were similar in both groups.
Results. The efficacy of tetracosactide exceeded that of dexamethasone: there were more responders to 
therapy in Group 1: 92.4% vs 72% (p = 0.0017). Tetracosactide produced faster results: 50.5% of patients in 
Group 1 experienced cessation of infantile spasms within the first 5 days of therapy versus 38.7% of pa-
tients in Group 2; infantile spasms ceased in 34% of patients in Group 1 on day 6–10, versus 22.2% of pa-
tients in Group 2. 74.6% of patients in Group 1 experienced normalization of EEG on day 10, versus 33.3% 
of patients in Group 2 (p = 0.04). A higher percentage of patients treated with dexamethasone exhibited 
multiregional activity on EEG by day 10. Tolerability was similar in both groups. All adverse effects were of 
mild to moderate severity
Conclusion. Tetracosactide therapy in combination with average therapeutic doses of valproate proved 
to be more effective in treating WS than the combination of dexamethasone and valproate.
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BACKGROUND
West syndrome (WS) is one of the most common epi-
leptic encephalopathies. While it affects predominant-
ly infants with various cerebral disorders, it may also 
present itself in initially healthy children. The absence 
of adequate therapy which allows to arrest infantile 
spasms (IS) and hypsarrhythmia in most cases leads to 
an regression of psychomotor development and severe 
disabilities. Development of effective treatment proto-
cols for WS is therefore an urgent matter of scientific 
and economic significance.
The attempts to develop effective treatment of WS 
has a long history and also connected with geograph-
ic peculiarities. For instance, in the USA and India, 
the adrenocorticotropic hormone (ACTH) has been 
the drug of first choice, whereas in Europe vigabatrin 
(VGB) was offered as first-line option alongside with 
ACTH and prednisone for initial therapy for IS that 
are symptomatic in etiology (Wheless et al., 2007). Re-
cently treatment methods for WS have been under re-
vision. Currently, preference is given to hormone ther-
apy. The exception are IS in tuberous sclerosis, because 
of its unparalleled efficacy. It is generally accepted that 
hormone therapy versus VGB results in a higher rate 
of IS cessation and EEG normalization, as well as bet-
ter other treatment outcomes, including cognitive im-
provement (Lux et al., 2004; Riikonen, 2014; Wilms-
hurst et al., 2015). Hormone therapy remains large-
ly empirical. The drug choice of hormone type is of-
ten defined by its availability in different countries. In 
the USA the natural ACTH is used, whereas in Europe 
– its synthetic version, tetracosactide (Riikonen, 2014) 
is used. In some countries, ACTH or tetracosactide is 
not approved; therefore corticosteroids (prednisolone, 
hydrocortisone, and dexamethasone) are mainly used. 
The data on the efficacy and tolerability of corticoster-
oids versus ACTH are different (Arya et al., 2012; Go et 
al., 2012; Jones et al., 2015). Comparative trials on effi-
cacy and tolerability of various hormone therapy pro-
tocols are limited. We have used the modified thera-
py protocol for treatment of WS, originally proposed 
by Prof. H. Siemes. The protocol included low doses of 
the hormones and therapeutic doses of valproate con-
currently (Siemes, 1997). Despite the lack of any accu-
rate evidence based on the efficacy of valproatefor the 
treatment of IS, it remains the drug of the first choice 
for the treatment of different seizure types and epilep-
sy syndromes.
AIM
The purpose of this study was to evaluate the short-term 
efficacy (cessation of IS and hypsarrhythmia) of both 
ACTH (Synacthen Depot) and dexamethasone when 
combined with sodium valproate (Depakine).
MATERIALS AND METHODS
Study design
A single center retrospective comparative observation-
al study was used as it closely resembling routine clini-
cal practice. The study population comprised 131 chil-
dren aged between 2 and 18 months, followed at the 
Novosibirsk City Center for Epilepsy and the Novosi-
birsk City Neurology Center “Sibneiromed” between 
1999 and 2009. Observation period in the study was ap-
proximately 45 days, with the majority of patients con-
tinuing follow up at the same facility for up to 10 years.
Study inclusion criteria:
1. 2–18 months of age.
2. Infantile spasms.
3. Hypsarrhythmia on interictal EEG.
4. Developmental delay or regression.
IS were characterized as brief severe axial muscles 
contractions (flexors, extensor, or mixed), lasting frac-
tions of a second, in clusters (5 to 50 per cluster), with 
multiple clusters daily, often upon awakening. IS were 
either symmetric or asymmetric, with head and eye de-
viation, or only in one side of the body. In rare scenari-
os we observed only a brief upward eye deviation with 
typical for IS ictal EEG pattern (Engel, 2001).
Hypsarrhythmia was defined as “…random high-vol-
tage slow waves and spikes. These spikes vary from mo-
ment to moment, both in location and duration. At ti-
mes they appear to be focal, and a few seconds later they 
seem to originate from multiple foci. Occasionally, the 
spike discharge becomes generalized, but it never appe-
ars as a rhythmically repetitive and highly organized pat-
tern that could be confused with a discharge of the petit 
mal variant type. … The abnormality is almost conti-
nual…” (Gibbs and Gibbs, 1952). Hypsarrhythmia was 
either classical or modified, the latter of several types: 
synchronized, asymmetrical, with sustained regional 
pattern, high amplitude asynchronous, or with suppres-
sion-burst pattern. Hypsarrhythmia was diagnosed by 
EEG during wakefulness and sleep. We recorded bioe-
lectrical brain activity and ECG simultaneously, using 
57Combined hormone therapy in West syndrome
Neurotravel and Encephalan-131-01 encephalographs. 
EEG results were evaluated by us.
According to the ILAE the classic triad of WS is rare. 
Due to early diagnosis and treatment, classical hypsar-
rhythmia is practically never found. Nowadays modi-
fied hypsarrhythmia or multiregional epileptiform dis-
charges are more often registered. There are also some 
difficulties in defining regression in children who have 
developmental delay and early debut IS. Taking in-
to consideration the fact mentioned above, when de-
scribing the syndrome, it is currently recommended to 
use the term “infantile spasms”. The name “West syn-
drome” is used only in rare cases (Pavone et al., 2015; 
Howell et al., 2016). However, due to the retrospective 
nature of the study, we continue to use the historical 
term “West syndrome”.
Exclusion criteria:
1. Atypical infantile spasms (IS with developmental 
retardation or regression without hypsarrhythmia, 
or hypsarrhythmia with developmental retardation 
without IS).
2. Absence of developmental delay or regression.
3. Use of antiepileptic drugs (AEDs) and/or hormones 
prior to the follow up.
4. Use of other AEDs, excluded valproic acid, and hor-
mones (tetracosactide and dexamethasone).
5. Hypersensitivity to valproic acid or liver disease.
6. Presence of infection disease accompanied by fever 
at the start of therapy.
7. Acute or chronic progredient diseases of CNS and 
other systems that could potentially compromise 
therapy outcomes.
8. Non compliance.
97 out of 131 patients matched all inclusion and ex-
clusion criteria. 34 patients were not included.
Treatment
None of the patients had previously received thera-
py. At the start of therapy, the majority of patients re-
ceived a combination of oral sodium valproate and in-
tramuscular injections of tetracosactide, while a minor-
ity of patients received a combination of oral sodium 
valproate and intramuscular injections of dexameth-
asone. 79 infants (Group 1), 53 males and 26 females, 
received synthetic ACTH, while 18 infants (Group 2), 
13 males and 5 females, received dexamethasone. The 
hormone therapy choices were dictated by drug avail-
ability in the healthcare system.
All patients received standard doses. Sodium val-
proate (Depakene syrup, Sanofi, France) was adminis-
tered at a daily dose of 30–40 mg/kg/d. The initial dose 
was 10 mg/kg/d, with a 10 mg/kg dose increase every 
second day according to H. Siemes treatment protocol. 
Tetracosactide (Synacthen Depot, Novartis, USA) ther-
apy at a daily dose of 0.03–0.05 mg/kg or dexametha-
sone (Dexasone, Polfa, Poland) therapy at a daily dose 
of 0.3–0.5 mg/kg were administered intramuscularly, 
according to the following schedule: one injection dai-
ly for 10 days, followed by 5 alternate-day injections, 
followed by 5 injections every third day. Patients were 
concurrently administered diuretics on the days of hor-
mone injections and received potassium, calcium and 
vitamin D daily. Other AEDs were not used.
All the patients were hospitalized for the whole pe-
riod of hormone therapy and were under twenty-four 
hour observation. Counting of seizures was carried out 
by parents and medical staff.
Efficacy
Primary endpoints were:
1. Percentage of patients with IS cessation by day 5.
2. Percentage of patients with IS cessation by day 10/11.
3. Percentage of patients with cessation of hypsarrhyth-
mia on EEG by day 10/11.
Secondary endpoints were:
1. Percentage of patients with IS cessation at hormone 
therapy completion.
2. Percentage of patients with ongoing IS at hormone 
therapy completion.
3. Percentage of patients with epileptic discharges in 
EEG by day 10/11.
Safety
Safety was assessed by recording spontaneously report-
ed adverse events throughout the study. Additionally, 
hematology, blood chemistry panel, and ECG were per-
formed every 10th days during the first month of ther-
apy. The presence of side effects was assessed accord-
ing to records in patient clinical chart.
Data processing
Student’s t-test for alternate groups and χ2 test were used 
to determine statistical differences between the groups.
Study design limitations
The major limitation was concurrent administering 
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of valproate and hormones, because at the start of the 
study in 1999 this type of formula was common. How-
ever, the titration rate and the maximum valproate 
therapeutic dose of 30–40 mg/kg were identical in both 
study groups. We believe that it made it possible to as-
sess the efficacy of tetracosactide versus dexametha-
sone. With concurrent administering of therapies, the 
difficulty lies in determining adverse effects. Definite-
ly, video EEG monitoring is ideal for determining the 
number of seizures, as there may be hidden IS. Unfor-
tunately, we did not have such a possibility at that time. 
Another design limitation was unequal numbers of pa-
tients in the groups due to the retrospective nature of 
the study. Also in this study it was possible to estimate 
only the short-term efficacy of this protocol.
Ethical Committee
Voluntary informed consent, approved by the Local 
Ethics Committee, was received for each patient.
RESULTS
Study groups
Overall, we provided initial treatment to 97 children 
with WS. The follow-up period lasted from one month 
to ten years. In the course of the study, patients were 
divided into 2 groups based on the type of hormone 
therapy.
Demographic data and medical history data are 
shown in Table 1.
The onset of IS in Group 1 occurred at the age range 
of 2–14 months, however, in the majority of cases on-
set occurring at 5–6 months; the onset of IS in Group 
2 occurred at the same age range of 2–14 months, how-
ever, in the majority of cases onset occured at 7 months 
(Figure 1).
The description of epileptic syndrome by study group 
is shown in Table 2.
Tables 1 and 2 demonstrate that despite the unequal 
Table 1. Demographic data in treatment groups
No. of patients
Group 1
(tetracosactide + valproate)
Group 2
(dexamethasone + valproate)
Total 79 18
Median age (months) 5.8 7.3
Male 53 13
Female 26 5
Male vs Female 2.04 2.6
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Table 2. Description of epileptic syndrome in treatment groups
Number of patients %
Group 1
(tetracosactide + valproate)
n = 79
Group 2
(dexamethasone + valproate)
n = 18
Epilepsy etiology
Hypoxic Ischemic Neonatal Encephalopathy  51 (64.6%)  13 (72.2%)
Malformations of cerebral cortical development  11 (13.9%)  2 (11.1%)
Metabolic disorders  5 (6.3%)  0
Chromosomal disorders  2 (2.5%)  0
Neuroinfections  2 (2.5%)  0
Cerebral hemorrhage  1 (1.3)  1 (5.5%)
Cryptogenic IS  7 (8.9%)  2 (11.1%)
Spasm types
Flexor IS  48 (60.7%)  12 (66.6%)
Extensor IS  12 (15.1%)  3 (16.6%)
Asymmetrical IS  4 (5.1%)  1 (5.5%)
Combination of IS  15 (18.9%)  2 (11.1%)
Clusters daily
Up to 5  61 (77.2%)  15 (83.3%)
Up to 10  13 (16.5%)  1 (5.5%)
> 10  5 (6.3%)  2 (11.1%)
Spasms per cluster
Up to 5  1 (1.2%)  0
Up to 10  46 (58.2%)  11 (61%)
Dozens  32 (40.5%)  7 (39%)
Hypsarrhythmia types
classical  21 (26.6%)  3 (16.6%)
synchronized  17 (21.5%)  5 (28%)
asymmetric  5 (6.3%)  0
with a consistent focus  13 (16.4%)  3 (16.6%)
high amplitude asynchronous  4 (5.1%)  1 (5.5%)
suppression-burst pattern  16 (24.1%)  6 (33.3%)
IS = infantile spasms
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numbers of patients in Group 1 and 2, the demograph-
ic data (age, gender) and the descriptions of epileptic 
syndrome (age at onset, types and frequency of IS, and 
hypsarrhythmia types) were similar in both groups.
Efficacy of hormone therapy
The results of hormone therapy are shown in Table 3. 
Thus, it can be seen from Table 3 that in most cases 
IS ceased during the first 5 days of hormone therapy. 
The protocol that included tetracosactide proved to 
be more effective for IS cessation. Also the disappear-
ance of hypsarrhythmia is achieved in most cases dur-
ing the first 10 days of hormone treatment. And herein 
the protocol included tetracosactide showed its great-
er efficacy. Epileptiform discharges on EEG (multire-
gional, focal and hypsarrhythmia) remained more of-
ten in patients of Group 2.
Tolerability
The data on adverse effects are summarized in Table 
4. Appetite increase and weight gain are predictable 
and unpreventable adverse effects of hormone thera-
py, and were not taken into account in comparing tet-
racosactide versus dexamethasone. Treatment had no 
adverse effects in 32/79 (40.5%) of patients on tetracos-
actide, and in more than 50% of patients on dexameth-
asone: 10/18 (55.6%).
Most adverse effects were mild, occurring on the sec-
ond week of hormone therapy, and did not require sus-
pension or cessation of therapy.
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DISCUSSION
There is no single globally accepted treatment protocol 
for West syndrome. Epilepsy centers in different coun-
tries follow individual treatment protocols, varying in 
chosen medications, their doses and therapy duration. 
The common goal is to ensure cessation of IS and nor-
malization of electroencephalograms. Similar therapy 
principles – start of treatment as soon as possible, min-
imal therapeutic dose of hormones with maximum ef-
ficacy – are widely used (Pellock et el., 2010; Riikonen, 
2014). There are more data on efficacy and tolerability 
of natural ACTH and its synthetic analogue, tetracos-
actide (Synacthen Depot), in the treatment of IS, com-
paring with efficacy and tolerability of corticosteroids 
(Riikonen, 2014; Wilmshurst et al., 2015). However, ef-
fective doses of the biologically equivalent ACTH and 
tetracosactide vary from 0.2 mg in Japan to 0.6 mg in 
the USA. Frequency of ACTH or tetracosactide admin-
istration also varies: once daily or once every other day. 
There are no clear guidelines for therapy discontinua-
tion: whether it should be gradual or immediate. Until 
recently, the general view was that the efficacy of tetra-
cosactide is higher than that of corticosteroids (Pellock 
et el., 2010; Arya et al., 2012; Go et al., 2012; Riikonen, 
2014; Shumiloff et al., 2013; Wilmshurst et al., 2015), 
while most recent research demonstrates higher effi-
cacy of prednisolone versus tetracosactide (Wanigas-
inghe et al., 2015).
We compared two therapy protocols. In the first one, 
tetracosactide was administered together with grad-
ually increased therapeutic doses of valproates, and 
in the second protocol, we administered dexametha-
sone. Titration and doses of valproate were identical in 
both groups, so we believe that it is possible to compare 
the efficacy and of tolerability of the two hormones. 
The efficacy of tetracosactide exceeded that of dexa-
methasone, i.e. the percentage of responders to thera-
py was significantly higher in Group 1: 92.4% vs 72% 
(p = 0.0017). Tetracosactide produced faster results in 
higher percentage of cases: 50.5% of patients in Group 
Number of patients (%)
Group 1
(tetracosactide + valproate)
n = 79
Group 2
(dexamethasone + valproate)
n = 18
Cessation of IS
First 5 days of therapy  40 (50.6%)  7 (38.7%)
Days 6–10  24 (34%)  4 (22.2%)
Days 11–30  9 (11.4%)  2 (11.1%)
IS ongoing
 6 (7.6%) (р = 0.0017)  5  (28%) (р = 0.0017)
EEG on Days 10-11 of hormone therapy
Without epileptiform discharges  59 (74.7%) (р = 0.4)  7 (38.9%) (р = 0.04)
Multiregional epileptiform discharges  1 (1.3%)  6 (33.3%)
Focal epileptiform discharges  14 (17.7)%  3 (16.7%)
Hypsarrhythmia  5 (6.%)  2 (11.1%)
Table 3. Efficacy of hormone therapy treatment groups
IS = infantile spasms
Table 4. Adverse effects and their frequency in hormone therapy combined with valproates
Number of patients (%)
Group 1
(tetracosactide + valproate)
n = 79
Group 2
(dexamethasone + valproate)
n = 18
Upper respiratory infections  21 (26.6%)  4 (22.2%)
Mucous membrane candidiasis  16 (20.2%)  1 (5.5%)
Hypopotassemia  12 (15.1%)  2 (11.1%)
Hypocalcemia  3 (3.8%)  1 (5.5%)
Thrombocytopenia  5 (6.3%)  0
Hyponatremia  0  1 (5.5%)
Iosif V. Volkov et al.
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1 experienced cessation of IS within the first 5 days of 
therapy versus 38.7% of patients in Group 2; IS ceased 
in 34% of patients in Group 1 (treated with tetracos-
actide) on days 6 through 10, versus 22.2% of patients 
in Group 2 (treated with dexamethasone). 74.6% of pa-
tients in Group 1 had normalization of EEG on day 10, 
versus 33.3% of patients in Group 2 (p = 0.04). A higher 
percentage of patients treated with dexamethasone ex-
hibited multiregional activity in EEG by day 10. Both 
protocols of hormone therapy demonstrated simi-
lar tolerability in patients. All patients in both groups 
displayed increased appetite and weight gain. Oth-
er adverse effects were demonstrated in 50% of cases, 
most frequently, upper respiratory infections and mu-
cous membrane candidiasis. All adverse effects were of 
mild and moderate severity, and did not require thera-
py discontinuation.
CONCLUSIONS
Tetracosactide (Synacthen Depot) therapy in combina-
tion with average therapeutic doses of valproates is more 
effective in treating WS than the combination of dexa-
methasone and valproate. Tetracosactide doses of 0.03–
0.05 mg/kg daily according to the treatment protocol 
are effective and well tolerable. Adverse effects are pre-
dictable and easily amenable to correction. Tolerabili-
ty is similar in both treatment protocols, with adverse 
effects that do not lead to the discontinuation of ther-
apy. Presented protocol leads to quick cessation of IS 
and hypsarrhythmia, it lasts for 35 days. A doctor who 
chooses any of the protocols for hormonal treatment of 
IS can plan the duration of therapy, its cost, necessary 
exams and their frequency during treatment and con-
comitant therapy as well as the expected efficacy and 
tolerability of the protocol.
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